Advisory Panel To Consider Ischemic Colitis Warning For Zelnorm
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Gastrointestinal Drugs Advisory Committee will consider whether labeling for Novartis' irritable bowel disease therapy Zelnorm should contain a warning for ischemic colitis.